Background: Chemotherapy is the basic approach to clinical tuberculosis control. Antituberculous therapy causesderangement of hepatic functions revealed by disturbed liver function tests. The incidence of side effects may varydepending upon a number of factors. The primary purpose of this study was to determine the relative and absolutehepatotoxicity of different antituberculous drug regimens in Pakistani population where majority of the tuberculouspatients belong to poor socioeconomic status. Methods: One hundred patients between 30 to 70 years of age withnewly diagnosed pulmonary tuberculosis were selected and divided into four groups on the basis of different drugregimens. Blood and urine tests of these patients were made. Liver function tests were performed before therapy andthen after one. two. three, six and nine months of treatment. Results <& Conclusions: Antituberculous therapy causesderangement of hepatic function to a variable extent in patients of four different antituberculous drug regimens understudy. Drug combination of Streptomycin. Isoniazid and Myambutol seem to be best tolerated of all the four regimens.Monitoring of the liver function in patients on antituberculous therapy indicated that liver dysfunction most frequentlyoccurs during first three months of therapy. There is a tendency for enzyme values to return to normal inspite ofcontinuous treatment. The mechanism underlying this adaptation to injury to the liver is unknown. Biochemical testsin the patients presenting with jaundice yielded the pattern of acute hepatocellular necrosis with high transaminasesand moderately elevated Alkaline Phosphatase. None of the patients had hepatitis associated antigen in their serum.


Hinshaw, C H and Murrey J F The abstract from

paper presented in Fifth Asia Pacific Congress on

diseases of the Chest. (1977)

khan I Adverse reaction of mil anti-tuberculosis

drugs with special reference to Rifampicin and

Pyrazinamide. The Challenge. 1984 Vol 25 No. 2

Peter J.R. Miller k S and Brown P Studies on the

metabolic basis of the genetically determined

capacities for Isoniazid activation in man

Pharmacol. Exp. Ther 1965150 298-304

Mitchell JR. Thorgeirsson. UP and Black M

Increased incidence of Isoniazid hepatitis in rapid

acetylastors and possible relation to hydrazine

metabolites. Clin Pharmacol Ther. 1975 – 18-70-

Nelson. SD. Snodgrass. W.R. Mitchell. JR>

Metabolic activation of hydrazine to reactive

intermediates mechanistic implications for

Isoniazid and Improniazid Jaundice (1975)

Survey report of Tuberculous Advisory

Committee. (1974)

Renault, H., Compasgon. P. Rapin. J/R and

Jacquot. C Syntheses de L. Ethambutol -14 C et

Pharma cocinetique Chez la Souris Eur. J Med.

Chem. Chemica Therapeutica 1978 13(6) 569.

Lis RH Tuberculosidal activity if Ethambutol in

Human alveolar macrophages A synopsis of the

Scientific Session. B Buenos Aires Argentina. Dec.


Bobrowitz. I.D. and Gokulana. K.S. Ethambutol in

the retreatment of Pulmonary Tuberculosis Dis

Chest 1965 48L 238.

Mandel. G.I. Interaction of interleukocytic bacteria

and antibiotics. J. Clin Invest. (1973)

Gonzaler. D.U. Adverse effects of anti-tuberculous

drugs causing changes in the treatment Tubercle.

Robson & Sullivan, F.M. Anti-tuberculous drugs

Pharmacol Rev. 1963 15 169

Hinshaw. C.H and Murray, JJ Diseases of the

Chest. 4th Eds. 1980

Pitts. F.W Tuberculosis. Prevention and therapy. In

Current Concepts of infectious diseases p 1974


William. C Bailey, Sally, I, Taylor, Harry, E

Dascomb. Morton and Zeskind. M Disturbed

hepatic function during Isoniazid Chemoprphlaxin

Am. Rev. of Respiratory Disease Vol. 107 (1973.

Scherer. P.K Sumer Field J a I. al. S And Sherlock.

S Rifampicin Hepatitis Lancet I 1974 421.

Harolod, I. Isreal. M.D Isoniazid associated

hepatitis Gastroenterology. 1975 69 539-542

Ronaq, Z.R. Mamranm. M.A Shaukat A. Liver

function tests in patients taking Rifampicin

Specialists 1986 50 – 56.

Richard. J Lederman. M D. Faith B and Paul. J

Exchange transfusion as treatment of acute hepatic

failure due to anti-tuberculous drugs Ann Inter

Med 68 (4), (1968)

Black, M Mitchell. Jr. Zimmerma. H.J Isoniazid

associated hepatitis in 114 patients

Gastroenterology. 1975 69 289 – 302.

Mitchell. J R. Isoniazid liver inquiry. Clinical

spectrum Pathology and probable pathologists.

Ann Inter, Med 1976 84-181 – 192.

Mcdermott. W Ormond. I., Muschenchem, C

Daschle. K and Thompsett. R. Pyrazinamide

Isoniazid in tuberculous. A. Rev. Tuber. 1954. 69

Pembran, R.A Handog. I.B Rai Secedes. T and

Widow. A controlled Clinical trial on the treatment

of pulmonary tuberculosis with a regimen

containing Rifampicin Isoniazid and Pyrazinamide

Meducation Foundation (1968)

Grilling. DJ Hepatic toxicity of antituberculous

regimens containing Isoniazid. Rifampicin and

Pyrazinamide. Tubercle. 1978: 59;73

Girdwood. R.H Clinical Pharmacology. 25th Eds.

: p; 37.

Robson, J. M and Sullivan F.M. Anti-tuberculous

drugs Pharmacol. Rev. 1963.15/ 169-223